TY  - JOUR
AU  - Rockstroh, Juergen K.
AU  - Plonski, Frank
AU  - Bansal, Meena
AU  - Faetkenheuer, Gerd
AU  - Small, Catherine B.
AU  - Asmuth, David M.
AU  - Pialoux, Gilles
AU  - Zhang-Roper, Rebecca
AU  - Wang, Ronnie
AU  - Pineda, Juan A.
AU  - Heera, Jayvant
PY  - 2017
DO  - 10.3851/IMP3116
SN  - 1359-6535
UR  - http://hdl.handle.net/10668/19340
T2  - Antiviral therapy
AB  - Background: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc-containing treatment regimens were not associated with increased hepatotoxicity.Methods: In this randomized,...
LA  - en
PB  - Int medical press ltd
KW  - Human-immunodeficiency-virus
KW  - Clinical-trials
KW  - Ccr5
KW  - Entry
KW  - Combination
KW  - Vicriviroc
KW  - Inhibitor
KW  - Mechanism
KW  - Phase-2
TI  - Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial
TY  - research article
VL  - 22
ER  -